CN102784203A - Tanreqing tablet and preparation method thereof - Google Patents
Tanreqing tablet and preparation method thereof Download PDFInfo
- Publication number
- CN102784203A CN102784203A CN2011101313156A CN201110131315A CN102784203A CN 102784203 A CN102784203 A CN 102784203A CN 2011101313156 A CN2011101313156 A CN 2011101313156A CN 201110131315 A CN201110131315 A CN 201110131315A CN 102784203 A CN102784203 A CN 102784203A
- Authority
- CN
- China
- Prior art keywords
- coating
- label
- acrylic resin
- weight portion
- following weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008630 tanreqing Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title description 13
- 239000003814 drug Substances 0.000 claims abstract description 20
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 239000011248 coating agent Substances 0.000 claims description 70
- 238000000576 coating method Methods 0.000 claims description 70
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 239000004925 Acrylic resin Substances 0.000 claims description 24
- 229920000178 Acrylic resin Polymers 0.000 claims description 24
- 239000000243 solution Substances 0.000 claims description 24
- 238000001035 drying Methods 0.000 claims description 20
- 239000012528 membrane Substances 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 239000000284 extract Substances 0.000 claims description 19
- BHQCQFFYRZLCQQ-UTLSPDKDSA-N ursocholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-UTLSPDKDSA-N 0.000 claims description 19
- 239000006071 cream Substances 0.000 claims description 18
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 18
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 18
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 18
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 15
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims description 15
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims description 15
- 229960003321 baicalin Drugs 0.000 claims description 15
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims description 15
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 15
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 15
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 15
- 238000010438 heat treatment Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 13
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 13
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 13
- 229930195725 Mannitol Natural products 0.000 claims description 13
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 13
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 13
- 229940074393 chlorogenic acid Drugs 0.000 claims description 13
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 13
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 13
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 13
- 239000000594 mannitol Substances 0.000 claims description 13
- 235000010355 mannitol Nutrition 0.000 claims description 13
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims description 12
- 229940024606 amino acid Drugs 0.000 claims description 12
- 239000012141 concentrate Substances 0.000 claims description 12
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 239000002244 precipitate Substances 0.000 claims description 12
- 239000007921 spray Substances 0.000 claims description 12
- 239000003172 expectorant agent Substances 0.000 claims description 11
- 230000003419 expectorant effect Effects 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims description 6
- 206010013786 Dry skin Diseases 0.000 claims description 6
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 6
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- 235000011941 Tilia x europaea Nutrition 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 6
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 6
- 229960003943 hypromellose Drugs 0.000 claims description 6
- 239000004571 lime Substances 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 229960001855 mannitol Drugs 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 238000007254 oxidation reaction Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 238000007127 saponification reaction Methods 0.000 claims description 6
- 239000007779 soft material Substances 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 229940032147 starch Drugs 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000001117 sulphuric acid Substances 0.000 claims description 6
- 235000011149 sulphuric acid Nutrition 0.000 claims description 6
- 238000001291 vacuum drying Methods 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 238000013270 controlled release Methods 0.000 abstract description 17
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 abstract 1
- 210000004051 gastric juice Anatomy 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 201000003453 lung abscess Diseases 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 239000005434 MCC/mannitol excipient Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a Tanreqing controlled release tablet; the controlled release tablet prepared in the invention nearly releases no drugs in artificially simulated gastric juice, but slowly and smoothly releases drugs in artificially simulated intestinal juice; the continuous release time of the drugs is up to 12 hours, even 24 hours, which avoids the peak-valley phenomenon of the blood drug concentration in the body.
Description
[technical field]
The present invention relates to a kind of Chinese medicine preparation of treating wind-warm lung-heat disease, specifically relate to clear controlled release tablet of expectorant heat and preparation method thereof.
[background technology]
Wind-warm and pulmonary heat syndrome is a kind of common, multiple respiratory tract disease, is common in diseases such as various pneumonia, bronchitis, pulmonary abscess and anemopyretic cold." Chinese medicine clinical guidance principle " spells out: wind-warm lung-heat disease is that to experience wind heat virus caused, and the four seasons all have, and two seasons of Winter-Spring multiple acute fever caused by exogenous pathogenic factors.Symptoms such as clinical normal appearance heating, cough, asthma, pulmonary lesion.Bring very big misery for patient's body and mind, seriously endangering people's physical and mental health.At present medical circles adopt the Western medicine antibiotic therapy for this type of disease more, as: a robe Qusong sodium, imipenum, a robe bark suffering, erythromycin and gentamycin etc.These medicines carry out heavy dose of disease controlling when severe infections appears in patient have certain advantage; But because bacterial drug resistance makes these antibiotic effective doses increasing; Thereby toxic and side effects also increases thereupon; Expense is also very expensive, and the antibiotic utilization rate of China hospital is higher than 30% international average level far away up to 80%.If the long-term heavy dose of abuse of antibiotic will make its sensitive bacterial produce drug resistance quickly, thereby make antibiotic curative effect decline, service life shorten in advance, thereby make the big increase of the National People's Congress that dies from these sensitive bacterials.The clear injection of expectorant heat is widely used in the diseases such as treating wind-warm lung-heat, but the Chinese medicine safety is low, poor stability, thereby the present invention provides a kind of safer more stable Chinese medicinal tablet.
[summary of the invention]
The object of the present invention is to provide a kind of controlled release preparation of treating traditional Chinese medical science wind-warm and pulmonary heat syndrome, be mainly used in the diseases such as cough, heating, asthma and pulmonary lesion that treatment pneumonia, bronchitis outbreak, pulmonary abscess and anemopyretic cold etc. cause.
The technical problem that the present invention solved realizes through following technical scheme:
The consumption of drug component of the present invention is also groped to sum up to draw through the inventor in a large number, and each amounts of components is for all to have better curative effect in the following weight parts scope:
Controlled release tablet of the present invention is made up of label and coating membrane,
1) said label is made up of the component of following weight portion:
2) said coating membrane is made up of the component of following weight portion:
Acrylic resin RS 12-14 part acrylic resin RL 2-4 part
Hydroxypropyl methyl cellulose phtalate 2.5-3.5 part dibutyl sebacate 4-10 part
Pulvis Talci 2-7 part.
Further be preferably:
1) said label is made up of the component of following weight portion:
2) said coating membrane is made up of the component of following weight portion:
Acrylic resin RS 12-14 part acrylic resin RL 2-3 part
Hydroxypropyl methyl cellulose phtalate 2.5-3 part dibutyl sebacate 4-8 part
Pulvis Talci 2-6 part.
Can also be preferably: 1) said label is made up of the component of following weight portion:
2) said coating membrane is made up of the component of following weight portion:
Acrylic resin RS 12-14 part acrylic resin RL 2-3 part
Hydroxypropyl methyl cellulose phtalate 2.5-3 part dibutyl sebacate 4-7 part
Pulvis Talci 2-6 part.
Can also be preferably: 1) said label is made up of the component of following weight portion:
2) said coating membrane is made up of the component of following weight portion:
3 parts of 13 parts of acrylic resin RL of acrylic resin RS
5 parts of 3 parts of dibutyl sebacates of Hydroxypropyl methyl cellulose phtalate
4 parts of Pulvis Talci.
Said total urso cholic acid makes through comprising the steps: Fel Ursi powder hydro-oxidation sodium solution heating saponification after 10-20 hour, is added dilute hydrochloric acid and transfers pH to 1.0-2.0, filter taking precipitate.
Said total amino acids makes through comprising the steps: Cornu Naemorhedi is added the sulphuric acid heating and refluxing extraction of 4mol/L, filter, filtrating is transferred pH to 3.5-5.0 with lime cream, filters, and filtrating adds the ethanol precipitate with ethanol, and cold preservation is left standstill, and filters, and gets the filtrating concentrate drying to dried cream.
Said Fructus Forsythiae extract makes through comprising the steps: with the Fructus Forsythiae decocte with water, collect water decoction, concentrate drying to dried cream.
The method for preparing of the controlled release tablet that described expectorant heat is clear: crude drug total urso cholic acid, total amino acids, baicalin, chlorogenic acid and the Fructus Forsythiae extract of label are pulverized the back cross 80 mesh sieves; Each adjuvant is pulverized the back and is crossed 80 mesh sieves, adds hypromellose K100M aqueous solution after total urso cholic acid, total amino acids, baicalin, chlorogenic acid, Fructus Forsythiae extract, starch, mannitol, microcrystalline Cellulose, hydroxyethyl-cellulose press the proportional quantity mixing, makes soft material; 20 mesh sieves are granulated; 30～50 ℃ of dryings 1～3 hour, granulate adds magnesium stearate; Mixing, tabletting promptly get label; Take by weighing the coating membrane composition of recipe quantity, be scattered in 80% ethanol and stir, the percentage composition that is mixed with solids in the solution is 5～10% coating solution, and is subsequent use; Coating pan inwall shop one deck coating solution to cleaning dries up, and forms the protecting film that alleviates the sharp impacts of label and coating pan wall and wear and tear; Get 1000 labels and put preheating 3～7min in the coating pan, keeping the ambient temperature in the coating pan is 30～40 ℃, opens air compressor; Adjusting pressure is 4～6MPa; The spray rate of spray gun is 2-4ml/min, on former label basis, increasing weight 2-3%, coated tablet is put into vacuum drying oven with the coating material coating; 30～50 ℃ of drying 10～14h promptly get.
[description of drawings]
Fig. 1: the release profiles of three batches of controlled release tablet.
[specific embodiment]
The investigation of the required microcrystalline cellulose/mannitol ratio of controlled release tablet
Add microcrystalline cellulose respectively: mannitol is the microcrystalline cellulose and the mannitol of 4: 20,6: 18,7: 16,9: 14 four different proportions; Wherein active component is: total urso cholic acid 20g, total amino acids 10g, baicalin 200g, chlorogenic acid 100g and Fructus Forsythiae extract 150g; Prepare the clear label of expectorant heat by the label method for preparing; Put coating in the coating pan, measure the release degree respectively:
Table 1 contains the controlled release tablet prescription form of different microcrystalline cellulose/mannitol ratios
Experimental result shows that with the minimizing of mannitol, the increase of microcrystalline cellulose consumption, rate of releasing drug slows down to some extent within the specific limits, but when microcrystalline cellulose and mannitol reached certain proportion, with the increase of microcrystalline cellulose consumption, rate of releasing drug was accelerated on the contrary; Analyze its reason, be since water solublity preferably mannitol certain osmotic pressure facilitation is arranged in label, along with the minimizing of its consumption; This short effect of oozing weakens; And with the increase of microcrystalline cellulose consumption, the hardness of label increases to some extent, thereby causes rate of releasing drug to slow down jointly; But when microcrystalline cellulose increases to certain proportion, mainly embody its disintegration, local disintegrate possibly take place after absorbing water through micropore clothing film in label in the clothing film, so rate of releasing drug increases on the contrary; And when microcrystalline cellulose/mannitol was 6: 18, prepared controlled release tablet release degree was with to work out standard more approaching.
According to the regulation of Chinese Pharmacopoeia to enteric coated preparation; And the specific (special) requirements of considering this preparation; Should guarantee that at first said preparation has suitable time lag, promptly can not release in the 2h in 0.1mol/L HCl, and should be according to zero order kinetics equation constant speed release medicine in the pH6.8 phosphate buffer; And should guarantee that release reaches more than 90% in the medicine 12h, to guarantee its relative bioavailability.According to embodiment 4 preparation controlled release tablet; Repeated experiments 6 times; Measure baicalin release degree, and obtain meansigma methods
result and see table 2:
Table 2 controlled release tablet release degree experimental result
Cumulative release degree-time graph is carried out the zero level equation model; Get equation Q%=8.3938T-7.0289 (R2=0.9951); This shows that the controlled release tablet experiment in vitro of embodiment 4 is cumulative release degree＜10% in the 2h in 0.1mol/L HCl, and in the pH6.8 phosphate buffer, press zero level equation constant speed release medicine in the 10h; And homogeneity and repeatability are all better between sheet and the sheet, and it is accurate to meet the release scale of being worked out basically.
Pressing three batches of controlled release tablet of method preparation of embodiment 4, measure baicalin cumulative release percentage rate respectively, is abscissa with the time T, and cumulative release degree Q is that vertical coordinate is drawn release profiles, and the result sees Fig. 1.Below through implementing to come further to set forth the method for preparing of medicine of the present invention.
The preparation of embodiment 1 controlled release tablet of the present invention:
1) label composition:
2) coating membrane composition:
Acrylic resin RS 12kg acrylic resin RL 2kg
Hydroxypropyl methyl cellulose phtalate 2.5kg dibutyl sebacate 4kg
Pulvis Talci 2kg.
Total urso cholic acid makes through comprising the steps: Fel Ursi powder hydro-oxidation sodium solution heating saponification after 10 hours, is added dilute hydrochloric acid and transfers pH to 1.0, filter taking precipitate; Total amino acids makes through comprising the steps: Cornu Naemorhedi is added the sulphuric acid heating and refluxing extraction of 4mol/L, filter, filtrating is transferred pH to 3.5 with lime cream, filters, and filtrating adds the ethanol precipitate with ethanol, and cold preservation is left standstill, and filters, and gets the filtrating concentrate drying to dried cream; Fructus Forsythiae extract makes through comprising the steps: with the Fructus Forsythiae decocte with water, collect water decoction, concentrate drying to dried cream;
Total urso cholic acid, total amino acids, baicalin, chlorogenic acid and Fructus Forsythiae extract are pulverized the back cross 80 mesh sieves, each adjuvant is pulverized the back and is crossed 80 mesh sieves, and total urso cholic acid, total amino acids, baicalin, chlorogenic acid, Fructus Forsythiae extract, starch, mannitol, microcrystalline Cellulose, hydroxyethyl-cellulose press adding hypromellose K100M aqueous solution behind the proportional quantity mixing; The system soft material, 20 mesh sieves are granulated, 30 ℃ of dryings 3 hours; Granulate; Add magnesium stearate, mixing, tabletting promptly get label; Take by weighing the coating membrane composition of recipe quantity, be scattered in 80% ethanol and stir, the percentage composition that is mixed with solids in the solution is 8% coating solution, and is subsequent use; Coating pan inwall shop one deck coating solution to cleaning dries up, and forms the protecting film that alleviates the sharp impacts of label and coating pan wall and wear and tear; Get 1000 labels and put preheating 5min in the coating pan, keeping the ambient temperature in the coating pan is 35 ℃, opens air compressor; Adjusting pressure is 4MPa; The spray rate of spray gun is 2ml/min, on former label basis, increasing weight 2%, coated tablet is put into vacuum drying oven with the coating material coating; 50 ℃ of dry 10h promptly get.
The preparation of embodiment 2 controlled release tablet of the present invention:
1) label composition:
2) coating membrane composition:
Acrylic resin RS 14kg acrylic resin RL 4kg
Hydroxypropyl methyl cellulose phtalate 3.5kg dibutyl sebacate 10kg
Pulvis Talci 7kg.
Total urso cholic acid makes through comprising the steps: Fel Ursi powder hydro-oxidation sodium solution heating saponification after 20 hours, is added dilute hydrochloric acid and transfers pH to 2.0, filter taking precipitate; Total amino acids makes through comprising the steps: Cornu Naemorhedi is added the sulphuric acid heating and refluxing extraction of 4mol/L, filter, filtrating is transferred pH to 5.0 with lime cream, filters, and filtrating adds the ethanol precipitate with ethanol, and cold preservation is left standstill, and filters, and gets the filtrating concentrate drying to dried cream; Fructus Forsythiae extract makes through comprising the steps: with the Fructus Forsythiae decocte with water, collect water decoction, concentrate drying to dried cream;
Total urso cholic acid, total amino acids, baicalin, chlorogenic acid and Fructus Forsythiae extract are pulverized the back cross 80 mesh sieves, each adjuvant is pulverized the back and is crossed 80 mesh sieves, and total urso cholic acid, total amino acids, baicalin, chlorogenic acid, Fructus Forsythiae extract, starch, mannitol, microcrystalline Cellulose, hydroxyethyl-cellulose press adding hypromellose K100M aqueous solution behind the proportional quantity mixing; The system soft material, 20 mesh sieves are granulated, 50 ℃ of dryings 1 hour; Granulate; Add magnesium stearate, mixing, tabletting promptly get label; Take by weighing the coating membrane composition of recipe quantity, be scattered in 80% ethanol and stir, the percentage composition that is mixed with solids in the solution is 10% coating solution, and is subsequent use; Coating pan inwall shop one deck coating solution to cleaning dries up, and forms the protecting film that alleviates the sharp impacts of label and coating pan wall and wear and tear; Get 1000 labels and put preheating 7min in the coating pan, keeping the ambient temperature in the coating pan is 40 ℃, opens air compressor; Adjusting pressure is 6MPa; The spray rate of spray gun is 4ml/min, on former label basis, increasing weight 3%, coated tablet is put into vacuum drying oven with the coating material coating; 30 ℃ of dry 14h promptly get.
The preparation of embodiment 3 controlled release tablet of the present invention:
1) label composition:
2) coating membrane composition:
Acrylic resin RS 14kg acrylic resin RL 3kg
Hydroxypropyl methyl cellulose phtalate 3kg dibutyl sebacate 8kg
Pulvis Talci 5kg.
Total urso cholic acid makes through comprising the steps: Fel Ursi powder hydro-oxidation sodium solution heating saponification after 15 hours, is added dilute hydrochloric acid and transfers pH to 1.5, filter taking precipitate; Total amino acids makes through comprising the steps: Cornu Naemorhedi is added the sulphuric acid heating and refluxing extraction of 4mol/L, filter, filtrating is transferred pH to 4.5 with lime cream, filters, and filtrating adds the ethanol precipitate with ethanol, and cold preservation is left standstill, and filters, and gets the filtrating concentrate drying to dried cream; Fructus Forsythiae extract makes through comprising the steps: with the Fructus Forsythiae decocte with water, collect water decoction, concentrate drying to dried cream;
Total urso cholic acid, total amino acids, baicalin, chlorogenic acid and Fructus Forsythiae extract are pulverized the back cross 80 mesh sieves, each adjuvant is pulverized the back and is crossed 80 mesh sieves, and total urso cholic acid, total amino acids, baicalin, chlorogenic acid, Fructus Forsythiae extract, starch, mannitol, microcrystalline Cellulose, hydroxyethyl-cellulose press adding hypromellose K100M aqueous solution behind the proportional quantity mixing; The system soft material, 20 mesh sieves are granulated, 45 ℃ of dryings 2 hours; Granulate; Add magnesium stearate, mixing, tabletting promptly get label; Take by weighing the coating membrane composition of recipe quantity, be scattered in 80% ethanol and stir, the percentage composition that is mixed with solids in the solution is 10% coating solution, and is subsequent use; Coating pan inwall shop one deck coating solution to cleaning dries up, and forms the protecting film that alleviates the sharp impacts of label and coating pan wall and wear and tear; Get 1000 labels and put preheating 6min in the coating pan, keeping the ambient temperature in the coating pan is 40 ℃, opens air compressor; Adjusting pressure is 5MPa; The spray rate of spray gun is 3ml/min, on former label basis, increasing weight 3%, coated tablet is put into vacuum drying oven with the coating material coating; 40 ℃ of dry 12h promptly get.
The preparation of embodiment 4 controlled release tablet of the present invention:
1) label composition:
2) coating membrane composition:
Acrylic resin RS 13kg acrylic resin RL 3kg
Hydroxypropyl methyl cellulose phtalate 3kg dibutyl sebacate 5kg
Pulvis Talci 4kg.
Total urso cholic acid makes through comprising the steps: Fel Ursi powder hydro-oxidation sodium solution heating saponification after 12 hours, is added dilute hydrochloric acid and transfers pH to 1.0, filter taking precipitate; Total amino acids makes through comprising the steps: Cornu Naemorhedi is added the sulphuric acid heating and refluxing extraction of 4mol/L, filter, filtrating is transferred pH to 5.0 with lime cream, filters, and filtrating adds the ethanol precipitate with ethanol, and cold preservation is left standstill, and filters, and gets the filtrating concentrate drying to dried cream; Fructus Forsythiae extract makes through comprising the steps: with the Fructus Forsythiae decocte with water, collect water decoction, concentrate drying to dried cream;
Total urso cholic acid, total amino acids, baicalin, chlorogenic acid and Fructus Forsythiae extract are pulverized the back cross 80 mesh sieves, each adjuvant is pulverized the back and is crossed 80 mesh sieves, and total urso cholic acid, total amino acids, baicalin, chlorogenic acid, Fructus Forsythiae extract, starch, mannitol, microcrystalline Cellulose, hydroxyethyl-cellulose press adding hypromellose K100M aqueous solution behind the proportional quantity mixing; The system soft material, 20 mesh sieves are granulated, 40 ℃ of dryings 2 hours; Granulate; Add magnesium stearate, mixing, tabletting promptly get label; Take by weighing the coating membrane composition of recipe quantity, be scattered in 80% ethanol and stir, the percentage composition that is mixed with solids in the solution is 9% coating solution, and is subsequent use; Coating pan inwall shop one deck coating solution to cleaning dries up, and forms the protecting film that alleviates the sharp impacts of label and coating pan wall and wear and tear; Get 1000 labels and put preheating 3min in the coating pan, keeping the ambient temperature in the coating pan is 40 ℃, opens air compressor; Adjusting pressure is 5MPa; The spray rate of spray gun is 4ml/min, on former label basis, increasing weight 2.5%, coated tablet is put into vacuum drying oven with the coating material coating; 40 ℃ of dry 14h promptly get.
Claims (6)
1. the clear tablet of expectorant heat is made up of label and coating membrane,
1) said label is made up of the component of following weight portion:
2) said coating membrane is made up of the component of following weight portion:
Acrylic resin RS 12-14 part acrylic resin RL 2-4 part
Hydroxypropyl methyl cellulose phtalate 2.5-3.5 part dibutyl sebacate 4-10 part
Pulvis Talci 2-7 part
2. the clear tablet of expectorant heat as claimed in claim 1 is characterized in that:
1) said label is made up of the component of following weight portion:
2) said coating membrane is made up of the component of following weight portion:
Acrylic resin RS 12-14 part acrylic resin RL 2-3 part
Hydroxypropyl methyl cellulose phtalate 2.5-3 part dibutyl sebacate 4-8 part
Pulvis Talci 2-6 part.
3. the clear tablet of expectorant heat as claimed in claim 1 is characterized in that:
1) said label is made up of the component of following weight portion:
2) said coating membrane is made up of the component of following weight portion:
Acrylic resin RS 12-14 part acrylic resin RL 2-3 part
Hydroxypropyl methyl cellulose phtalate 2.5-3 part dibutyl sebacate 4-7 part
Pulvis Talci 2-6 part.
4. the clear tablet of expectorant heat as claimed in claim 1 is characterized in that:
1) said label is made up of the component of following weight portion:
2) said coating membrane is made up of the component of following weight portion:
3 parts of 13 parts of acrylic resin RL of acrylic resin RS
5 parts of 3 parts of dibutyl sebacates of Hydroxypropyl methyl cellulose phtalate
4 parts of Pulvis Talci.
5. like the clear tablet of the arbitrary described expectorant heat of claim 1-4, said total urso cholic acid makes through comprising the steps: Fel Ursi powder hydro-oxidation sodium solution heating saponification after 10-20 hour, is added dilute hydrochloric acid and transfers pH to 1.0-2.0, filter taking precipitate.Said total amino acids makes through comprising the steps: Cornu Naemorhedi is added the sulphuric acid heating and refluxing extraction of 4mol/L, filter, filtrating is transferred pH to 3.5-5.0 with lime cream, filters, and filtrating adds the ethanol precipitate with ethanol, and cold preservation is left standstill, and filters, and gets the filtrating concentrate drying to dried cream.Said Fructus Forsythiae extract makes through comprising the steps: with the Fructus Forsythiae decocte with water, collect water decoction, concentrate drying to dried cream.
6. like the method for preparing of the clear tablet of the arbitrary described expectorant heat of claim 1-4, it is characterized in that this method is:
Crude drug total urso cholic acid, total amino acids, baicalin, chlorogenic acid and the Fructus Forsythiae extract of label are crossed 80 mesh sieves, and each adjuvant is crossed 80 mesh sieves, total urso cholic acid, total amino acids, baicalin, chlorogenic acid, Fructus Forsythiae extract, starch, mannitol, microcrystalline Cellulose, hydroxyethyl-cellulose is pressed add hypromellose K100M aqueous solution behind the proportional quantity mixing; The system soft material, 20 mesh sieves are granulated, 30～50 ℃ of dryings 1～3 hour; Granulate; Add magnesium stearate, mixing, tabletting promptly get label; Take by weighing the coating membrane composition of recipe quantity, be scattered in 80% ethanol and stir, the percentage composition that is mixed with solids in the solution is 5～10% coating solution, and is subsequent use; Coating pan inwall shop one deck coating solution to cleaning dries up, and forms the protecting film that alleviates the sharp impacts of label and coating pan wall and wear and tear; Get 1000 labels and put preheating 3～7min in the coating pan, keeping the ambient temperature in the coating pan is 30～40 ℃, opens air compressor; Adjusting pressure is 4～6MPa; The spray rate of spray gun is 2-4ml/min, on former label basis, increasing weight 2-3%, coated tablet is put into vacuum drying oven with the coating material coating; 30～50 ℃ of drying 10～14h promptly get.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101313156A CN102784203A (en) | 2011-05-20 | 2011-05-20 | Tanreqing tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101313156A CN102784203A (en) | 2011-05-20 | 2011-05-20 | Tanreqing tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102784203A true CN102784203A (en) | 2012-11-21 |
Family
ID=47149923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101313156A Pending CN102784203A (en) | 2011-05-20 | 2011-05-20 | Tanreqing tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102784203A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5482718A (en) * | 1994-03-23 | 1996-01-09 | Hoffmann-La Roche Inc. | Colon-targeted delivery system |
| CN1060050C (en) * | 1994-04-05 | 2001-01-03 | 曹春林 | Jiawei double coptis medicament and preparing method thereof |
| CN1682719A (en) * | 2005-03-01 | 2005-10-19 | 沈阳药科大学 | Enteric-coated sustained-release tablet containing huperzine A and preparation method thereof |
| CN1754542A (en) * | 2004-09-29 | 2006-04-05 | 上海圣英生物科技有限公司 | Compound pharmaceutical composition for treating wind-warm lung-heat disease and its preparation method |
| CN1947746A (en) * | 2005-10-14 | 2007-04-18 | 上海凯宝药业有限公司 | Tanreqing medicine for cleaning phlegm-heat and its pren. method |
| CN101375849A (en) * | 2007-08-27 | 2009-03-04 | 湖南正清制药集团股份有限公司 | Novel dosage form of sinomenine medicament or hydrochlorate thereof and preparation technique thereof |
| WO2010041279A2 (en) * | 2008-10-08 | 2010-04-15 | V.B. Medicare Pvt. Ltd. | Sustained release drug delivery system |
-
2011
- 2011-05-20 CN CN2011101313156A patent/CN102784203A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5482718A (en) * | 1994-03-23 | 1996-01-09 | Hoffmann-La Roche Inc. | Colon-targeted delivery system |
| CN1060050C (en) * | 1994-04-05 | 2001-01-03 | 曹春林 | Jiawei double coptis medicament and preparing method thereof |
| CN1754542A (en) * | 2004-09-29 | 2006-04-05 | 上海圣英生物科技有限公司 | Compound pharmaceutical composition for treating wind-warm lung-heat disease and its preparation method |
| CN1682719A (en) * | 2005-03-01 | 2005-10-19 | 沈阳药科大学 | Enteric-coated sustained-release tablet containing huperzine A and preparation method thereof |
| CN1947746A (en) * | 2005-10-14 | 2007-04-18 | 上海凯宝药业有限公司 | Tanreqing medicine for cleaning phlegm-heat and its pren. method |
| CN101375849A (en) * | 2007-08-27 | 2009-03-04 | 湖南正清制药集团股份有限公司 | Novel dosage form of sinomenine medicament or hydrochlorate thereof and preparation technique thereof |
| WO2010041279A2 (en) * | 2008-10-08 | 2010-04-15 | V.B. Medicare Pvt. Ltd. | Sustained release drug delivery system |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104383123A (en) | Method for preparing golden camellia lipid-lowering blood sugar-reducing preparation | |
| CN104000796A (en) | Coating auxiliary materials, preparation method and coating method for Chinese herb extract preparations | |
| CN102526427B (en) | Traditional Chinese medicinal composition for treating gastrointestinal diseases and quality inspection method | |
| CN103142539A (en) | Alginic sodium diester controlled-release tablet and preparation method thereof | |
| CN102441019A (en) | Traditional Chinese medicine chrysanthemum buccal tablet | |
| CN102210773B (en) | Chinese medicinal cataplasm for treating infantile pneumonia, preparation method thereof and application thereof | |
| CN102784203A (en) | Tanreqing tablet and preparation method thereof | |
| CN104523952A (en) | Chinese herbal medicine composition for treating chicken influenza | |
| CN105560207B (en) | A kind of aurantiin controlled release capsule and preparation method thereof | |
| CN103705890A (en) | Pharmaceutical composition with function of removing heat from lung to relieve cough | |
| CN102836254A (en) | Medicine composition for treating infectious bursal diseases of chickens and preparation method thereof | |
| CN103933002A (en) | Scutellaria baicalensis total flavonoid sustained release tablet and preparation method thereof | |
| CN101007071A (en) | Traditional Chinese medicine for treating acute and chronic gastroenteritis and bacterial dysentery and its processing technology | |
| CN102416066A (en) | A traditional Chinese medicine preparation for treating throat and oral diseases and its preparation method | |
| CN103142504B (en) | PGMS (Propylene Glycol Mannate Sulfate) sustained-release granule and preparation method thereof | |
| CN103142540A (en) | PGMS (Propylene Glycol Mannate Sulfate) controlled-release tablet and preparation method thereof | |
| CN102429980A (en) | Cold granules and preparation method thereof | |
| CN115531463A (en) | Traditional Chinese medicine for treating hyperlipidemia | |
| CN101313941A (en) | A kind of compound reducing fat pellet preparation and preparation method thereof | |
| CN101099730A (en) | Oral solid preparation containing ambroxol hydrochloride and guaifenesin active components | |
| CN108686031B (en) | Traditional Chinese medicine composition for treating influenza and preparation method thereof | |
| CN103933376B (en) | Medicinal composition for treating chronic bronchitis | |
| CN103463537B (en) | Medicament for treating infantile asthma | |
| CN105147912A (en) | Traditional Chinese medicine composition for cough and asthma of poultry | |
| CN111000853A (en) | Application of Quzhazhigan in preparation of products for treating and/or preventing respiratory system diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20121121 |